{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:03:43Z","timestamp":1793361823583,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T00:00:00Z","timestamp":1420675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s11060-014-1710-0","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T03:35:18Z","timestamp":1420601718000},"page":"313-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas"],"prefix":"10.1007","volume":"122","author":[{"given":"St\u00e9phane","family":"Goutagny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Esposito-Farese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Trunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mawrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Bernardeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Larroque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sterkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Kalamarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,8]]},"reference":[{"issue":"2","key":"1710_CR1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A(2):327\u2013332","journal-title":"Am J Med Genet A"},{"issue":"9679","key":"1710_CR2","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373(9679):1974\u20131986","journal-title":"Lancet"},{"issue":"6","key":"1710_CR3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1227\/NEU.0b013e31828bae28","volume":"72","author":"M Peyre","year":"2013","unstructured":"Peyre M, Goutagny S, Bah A, Bernardeschi D, Larroque B, Sterkers O, Kalamarides M (2013) Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery 72(6):907\u2013913","journal-title":"Neurosurgery"},{"issue":"3","key":"1710_CR4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1227\/01.NEU.0000255340.26027.53","volume":"60","author":"D Mathieu","year":"2007","unstructured":"Mathieu D, Kondziolka D, Flickinger JC, Niranjan A, Williamson R, Martin JJ, Lunsford LD (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control complications and hearing preservation rates. Neurosurgery 60(3):460\u2013468","journal-title":"Neurosurgery"},{"issue":"3","key":"1710_CR5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1227\/NEU.0000000000000264","volume":"74","author":"GW Mallory","year":"2014","unstructured":"Mallory GW, Pollock BE, Foote RL, Carlson ML, Driscoll CL, Link MJ (2014) Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes. Neurosurgery 74(3):292\u2013301","journal-title":"Neurosurgery"},{"issue":"4","key":"1710_CR6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358\u2013367","journal-title":"N Engl J Med"},{"issue":"11","key":"1710_CR7","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/annonc\/mdq566","volume":"21","author":"V-F Mautner","year":"2010","unstructured":"Mautner V-F, Nguyen R, Knecht R, Bokemeyer C (2010) Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 21(11):2294\u20132295","journal-title":"Ann Oncol"},{"issue":"6","key":"1710_CR8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33(6):1046\u20131052","journal-title":"Otol Neurotol"},{"issue":"4","key":"1710_CR9","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdr012","volume":"22","author":"S Goutagny","year":"2011","unstructured":"Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M (2011) Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 22(4):990\u2013991","journal-title":"Ann Oncol"},{"issue":"3","key":"1710_CR10","doi-asserted-by":"crossref","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","volume":"8","author":"FP Nunes","year":"2013","unstructured":"Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG 2nd, Stemmer-Rachamimov AO, Plotkin SR (2013) Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS ONE 8(3):e59941","journal-title":"PLoS ONE"},{"issue":"6","key":"1710_CR11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","volume":"73","author":"KM Slusarz","year":"2014","unstructured":"Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR (2014) Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 73(6):1197\u20131204","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1710_CR12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","volume":"31","author":"SR Plotkin","year":"2010","unstructured":"Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG (2010) Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 31(7):1135\u20131143","journal-title":"Otol Neurotol"},{"issue":"9","key":"1710_CR13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, Hochman T, Goldberg JD, Koch KM, Golfinos JG, Roland JT, Allen JC (2012) Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 14(9):1163\u20131170","journal-title":"Neuro Oncol"},{"issue":"5","key":"1710_CR14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","volume":"10","author":"MF James","year":"2012","unstructured":"James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, Gusella JF, Stemmer-Rachamimov AO, Ramesh V (2012) Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res 10(5):649\u2013659","journal-title":"Mol Cancer Res"},{"issue":"4","key":"1710_CR15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/neuonc\/not242","volume":"16","author":"M Giovannini","year":"2014","unstructured":"Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S, Kalamarides M (2014) mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol 16(4):493\u2013504","journal-title":"Neuro Oncol"},{"issue":"9861","key":"1710_CR16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre randomised placebo-controlled phase 3 trial. Lancet 381(9861):125\u2013132","journal-title":"Lancet"},{"issue":"21 Suppl 1","key":"1710_CR17","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih CS, Widemann BC, RESIC (2013) Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81(21 Suppl 1):S33\u2013S40","journal-title":"Neurology"},{"issue":"3","key":"1710_CR18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0194-5998(95)70101-X","volume":"113","author":"American Academy of Otolaryngology-Head and Neck Surgery Foundation Committee on Hearing and Equilibrium","year":"1995","unstructured":"American Academy of Otolaryngology-Head and Neck Surgery Foundation Committee on Hearing and Equilibrium (1995) Guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). Otolaryngol Head Neck Surg 113(3):179\u2013180","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"11","key":"1710_CR19","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/1078-0432.CCR-04-2550","volume":"11","author":"C Mawrin","year":"2005","unstructured":"Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, Pambor C, Vorwerk CK, Firsching R, Lendeckel U, Dietzmann K (2005) Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res 11(11):4074\u20134082","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1710_CR20","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","volume":"19","author":"D Pachow","year":"2013","unstructured":"Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E, Mawrin C (2013) mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res 19(5):1180\u20131189","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1710_CR21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","volume":"20","author":"RP AHern","year":"2001","unstructured":"AHern RP (2001) Sample size tables for exact single-stage phase II designs. Stat Med 20(6):859\u2013866","journal-title":"Stat Med"},{"key":"1710_CR22","unstructured":"Bates D, Maechler M, Bolker B, WalkerS (2014) lme4: Linear mixed-effects models using Eigen and S4. R package version 1.1-6. http:\/\/CRAN.R-project.org\/package=lme4 . Accessed May 2014"},{"key":"1710_CR23","volume-title":"Models for discrete longitudinal data","author":"G Verbeke","year":"2005","unstructured":"Verbeke G, Molenberghs G (2005) Models for discrete longitudinal data. Springer, New York"},{"issue":"15","key":"1710_CR24","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V (2009) NF2\/merlin is a novel negative regulator of mTOR complex 1 and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29(15):4250\u20134261","journal-title":"Mol Cell Biol"},{"issue":"5","key":"1710_CR25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","volume":"16","author":"BC Widemann","year":"2014","unstructured":"Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM (2014) Phase 2 randomized flexible crossover double-blinded placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol 16(5):707\u2013718","journal-title":"Neuro Oncol"},{"issue":"1","key":"1710_CR26","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MAO.0000000000000239","volume":"35","author":"SR Plotkin","year":"2014","unstructured":"Plotkin SR, Merker VL, Muzikansky A, Barker FG 2nd, Slattery W 3rd (2014) Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 35(1):e50\u2013e56","journal-title":"Otol Neurotol"},{"issue":"2","key":"1710_CR27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Hagiwara M, Giancotti FG, Filatov A, Derman A, Hochman T, Goldberg JD, Vega E, Wisoff JH, Golfinos JG, Merkelson A, Roland JT, Allen JC (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 16(2):292\u2013297","journal-title":"Neuro Oncol"},{"issue":"2","key":"1710_CR28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358(2):140\u2013151","journal-title":"N Engl J Med"},{"issue":"1","key":"1710_CR29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3171\/2012.3.JNS111649","volume":"117","author":"MS Dirks","year":"2012","unstructured":"Dirks MS, Butman JA, Kim HJ, Wu T, Morgan K, Tran AP, Lonser RR, Asthagiri AR (2012) Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg 117(1):109\u2013117","journal-title":"J Neurosurg"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1710-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-014-1710-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1710-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T05:53:28Z","timestamp":1566194008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-014-1710-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["1710"],"URL":"https:\/\/doi.org\/10.1007\/s11060-014-1710-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,8]]}}}